New hope for rare fat disorder: drug trial targets dangerous blood sugar and fats
NCT ID NCT04159415
Summary
This study tested an experimental drug called REGN4461 in people with generalized lipodystrophy, a rare disorder where the body cannot store fat properly. The main goal was to see if the drug could help lower high blood sugar and high triglyceride (fat) levels in the blood. Sixteen participants with these specific metabolic problems were randomly assigned to receive either the drug or a placebo for 8 weeks to measure its effects and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Research Site
Bethesda, Maryland, 20892, United States
-
Regeneron Research Site
Ann Arbor, Michigan, 48105, United States
-
Regeneron Research Site
Dallas, Texas, 75390, United States
-
Regeneron Research Site
Piura, 2665, Peru
-
Regeneron Research Site
Moscow, 117036, Russia
-
Regeneron Research Site
Ankara, 06230, Turkey (Türkiye)
-
Regeneron Research Site
Diyarbakır, 21808, Turkey (Türkiye)
-
Regeneron Research Site
Izmir, 35100, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.